Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

Gail B. Cohen
Corporate Communications and Investor Relations
917-214-6603 i?Professor Woodcock is an independent consultant to Theravance Biopharma and is reimbursed on an hourly basis for his consultancy services
ii?The Lancet,?March 13, 2020, "COVID-19: consider cytokine storm syndromes and immunosuppression" Mehta, McAuley, Brown, Sanchez, Tattersall, Manson, et al. SOURCE Theravance Biopharma, Inc.
